Abstract: The present invention addresses a need for improved treatments for filovirus infections. This invention provides an isolated humanized anti-filovirus glycoprotein pre-fusion core antibody comprising a framework region having a sequence of 95% or greater identity to a human antibody framework region. Also provided is a method of treating and/or inhibiting a filovirus infection in a subject comprising administering to the subject an amount of any of the antibodies described herein, or an amount of an antigen-binding fragment thereof. Also provided is composition comprising any of the antibodies described herein, or or an amount of an antigen-binding fragment thereof. In an embodiment, the composition comprises a pharmaceutically acceptably carrier.
Type:
Application
Filed:
August 6, 2015
Publication date:
July 20, 2017
Applicants:
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC., THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO, U.S. ARMY MEDICAL RESEARCH AND MATERIAL COMMAND
Inventors:
Jonathan R. Lai, Jayne F. Koellhoffer, Julia Frei, Kartik Chandran, Sachdev Sidhu, Gang Chen, John M. Dye, Samantha Zak
Abstract: Inhibitors of Plasmodium falciparum equilibrative nucleoside transporter type 1 are identified and methods of use as anti-parasitic compounds are provided.
Type:
Grant
Filed:
June 26, 2014
Date of Patent:
July 4, 2017
Assignees:
THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK, ALBERT EINSTEIN COLLEGE OF MEDICINE, INC.
Inventors:
Myles Akabas, Ithiel James Frame, Donald W. Landry, Roman Deniskin, Shixian Deng, Alison Rinderspacher
Abstract: A composition is provided comprising an oligonucleotide aptamer conjugated to an antigen, wherein the aptamer is directed against a cell-surface target of an antigen-presenting cell. Also provided are methods of delivering an antigen to a dendritic cell and of eliciting an immune response in a subject.
Type:
Grant
Filed:
July 3, 2013
Date of Patent:
June 27, 2017
Assignee:
Albert Einstein College of Medicine, Inc.
Inventors:
Matthew Levy, Deborah Palliser, Brian Christopher Wengerter, Steven Craig Almo
Abstract: Methods and assays are disclosed for treating a subject with a hantavirus infection using an agent that binds to proto cadhenn-1 (PCDH1) or inhibits expression of protocadherin-1 (PCDH1).
Type:
Application
Filed:
February 25, 2015
Publication date:
June 22, 2017
Applicant:
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC.
Inventors:
Kartik Chandran, Thijin R. Brummelkamp, Lucas T. Jae, Rohit K. Jangra
Abstract: The present invention relates to 3-hydroxypyrrolidine compounds of the general formula (1) which are inhibitors of 5?-methylthioadenosine phosphorylase or 5?-methylthioadenosine nucleosidase. The invention also relates to the use of these compounds in the treatment of diseases or conditions in which it is desirable to in 5?-methylthioadenosine phosphorylase or 5?-methylthioadenosine nucleosidase including cancer, and to pharmaceutical compositions containing the compounds.
Type:
Application
Filed:
November 10, 2016
Publication date:
June 15, 2017
Applicants:
VICTORIA LINK LIMITED, ALBERT EINSTEIN COLLEGE OF MEDICINE, INC.
Inventors:
Gary Brian Evans, Alistair Ian Longshaw, Vern L. Schramm, Peter Charles Tyler
Abstract: Methods of treating infections due to Helicobacter pylori (H. pylori), in particular in subjects having a peptic ulcer, are disclosed where the methods comprise administering inhibitors of H. pylori MTAN (5?-methylthioadenosine nucleosidase) to the subject.
Type:
Application
Filed:
February 6, 2015
Publication date:
June 15, 2017
Applicant:
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC.
Inventors:
Vern L. Schramm, Keith Clinch, Shivali Ashwin Gulab
Abstract: Methods are disclosed for identifying activators and inhibitors of actions of interleukin-34 (IL-34) that are independent of the colony stimulating factor-1 (CSF-1) receptor (CSF-1R) and play a role in development, homeostasis and disease.
Type:
Grant
Filed:
May 19, 2014
Date of Patent:
June 6, 2017
Assignee:
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC.
Inventors:
Evan Richard Stanely, Sayan Nandi, Yee-Guide Yeung
Abstract: Methods and compositions are provided for alleviating and/or preventing one or more side effects associated with exposure to radiation in a subject exposed to radiation or at risk for exposure to radiation comprising oral administration to the subject of an amount of an edible source of melanin effective to alleviate a side effect associated with radiation.
Type:
Application
Filed:
August 8, 2016
Publication date:
May 11, 2017
Applicant:
Albert Einstein College of Medicine, Inc.
Abstract: Described herein is a method of preparing a hybrid hydrogel paramagnetic nanoparticle. In certain embodiments, the hybrid hydrogel paramagnetic nanoparticle comprises a therapeutic agent. In certain embodiments, the nanoparticle contains alcohol. In certain embodiments, the nanoparticles incorporate fatty acids. Also described herein, is a method of preparing a hybrid hydrogel NO-releasing nanoparticle. In another embodiment, provided herein is a method of preparing a S-nitrosocaptopril hydrogel nanoparticle. Also described herein is a method of preparing a curcumin-based hydrogel nanoparticle. Further, described herein is a method for treating a bacterial infection in a burn wound using curcumin-based hydrogel nanoparticles. Also provided herein is a method of treating a fungal infection using photoactivated curcumin-based hydrogel nanoparticles. In certain embodiments, the fungal infection is caused by dermatophytic fungi.
Type:
Application
Filed:
June 11, 2015
Publication date:
May 4, 2017
Applicant:
Albert Einstein College of Medicine, Inc.
Inventors:
Joel M. FRIEDMAN, Mahantesh S. NAVATI, Adam J. FRIEDMAN, Parimala NACHARAJU, Aimee KRAUSZ
Abstract: Isolated mutant Mycobacterium tuberculosis bacteria comprising a deletion in the ESAT-6 gene cluster region 3 (esx-3 region) are provided, as well as compositions comprising such, methods of production thereof and methods of use thereof.
Type:
Grant
Filed:
May 10, 2013
Date of Patent:
May 2, 2017
Assignee:
Albert Einstein College of Medicine, Inc.
Abstract: A method of delivering a cargo agent into cytosol of a cell can include: providing the delivery system of one of the embodiments described herein having the first and second delivery platforms; and administering the delivery system to a cell so as to cause targeting of two features on the cell so as to: cause endocytosis of the first and second delivery platforms of the delivery system into a common endosome, destabilize the endosome of the cell having the delivery system, release the cargo agent from the second linker; and release the cargo agent from the destabilized endosome into cytosol of the cell. A method of treating a disease can include: performing the method of method of delivering a cargo agent into cytosol of a cell in a subject having a disease, wherein the cargo agent is a therapeutic agent for the disease.
Type:
Grant
Filed:
October 13, 2014
Date of Patent:
May 2, 2017
Assignees:
The Universit of Kansas, Albert Einstein College of Medicine, Inc.
Inventors:
Blake R. Peterson, Liang Xu, Matthew Levy
Abstract: Method and compositions for treating type-2 diabetes in a subject are provided comprising administering to the subject an amount of an inhibitor of a TGF-beta.
Type:
Application
Filed:
July 17, 2015
Publication date:
April 27, 2017
Applicant:
Albert Einstein College of Medicine, Inc.
Abstract: Methods are provided for identifying an agent that directly modulates a Bcl-2- associated x-protein (BAX) by promoting or disrupting dimerization of the BAX. Agents that directly modulate BAX by affecting dimerization are also provided.
Type:
Application
Filed:
May 28, 2015
Publication date:
April 27, 2017
Applicant:
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC.
Abstract: Disclosed are methods and compositions for treating pulmonary arterial hypertension and/or obesity using inhibitors of prostaglandin transporter (PGT) activity.
Type:
Grant
Filed:
June 17, 2014
Date of Patent:
March 28, 2017
Assignee:
Albert Einstein College of Medicine, Inc.
Abstract: Methods are disclosed for treating multiple sclerosis comprising administering an agent that reduces expression and/or activity of Allograft inflammatory factor-1 (Aif-1) in a subject and for screening for such agents.
Type:
Application
Filed:
May 6, 2015
Publication date:
March 16, 2017
Applicant:
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC.
Inventors:
Nicholas Ernst Smit SIBINGA, Prameladevi CHINNASAMY, Sarah E. LUTZ
Abstract: Compounds, compositions and methods are provided for selectively activating chaperone-mediated autophagy (CMA), protecting cells from oxidative stress, proteotoxicity and lipotoxicity, and/or antagonizing activity of retinoic acid receptor alpha (RAR?) in subjects in need thereof.
Type:
Application
Filed:
October 20, 2016
Publication date:
February 9, 2017
Applicant:
Albert Einstein College of Medicine, Inc.
Inventors:
Ana Maria Cuervo, Evripidis Gavathiotis, Qisheng Xin, Bhaskar C. Das
Abstract: Methods are provided for treating metastatic cancer in patients having metastatic cancer or for preventing metastasis in cancer patients at risk for metastasis comprising administering to the patient an antibody to B7x, or an active antibody fragment that binds B7x, in an amount effective to treat or prevent metastasis.
Type:
Application
Filed:
August 31, 2016
Publication date:
February 2, 2017
Applicants:
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC., SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH
Abstract: A method of diagnosis and treatment of tumors using High Intensity Focused Ultrasound is provided. The method of diagnosing the presence of a tumor in a patient comprises the steps of subjecting a tumor to high intensity focused ultrasound (HIFU) to cause the tumor cells to release cellular material and evaluating the cellular material for a tumor marker. The method of treating a tumor in a patient can also comprise the step of subjecting a tumor to high intensity focused ultrasound (HIFU) to provoke an immune response.
Type:
Application
Filed:
September 29, 2016
Publication date:
January 19, 2017
Applicants:
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC., SONACARE MEDICAL, LLC
Inventors:
Narendra T. Sanghvi, Chandan Guha, Russell James Fedewa, Roy Francis Carlson, Ralf Seip, Wo-Hsing Chen